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Abstract
Glucose-6-phosphatase (G6Pase) is a multiple protein complex in the endoplasmic reticulum (ER) that includes a mechanism (known as
T3) for glucose exit from the ER to the cytosol. The molecular identity of T3 is not known. T3 has been shown to be functional in the absence
of GLUT2, indicating that it is not GLUT2. Here we found a 55-kDa protein in high-density microsomal fraction (HDM) of rat hepatocytes
that is recognized by polyclonal GLUT2 antibody raised against the GLUT2 C-terminal 14-amino-acid-sequence peptide. HDM contained
calnexin but no integrin-h1 or Na/K ATPase in Western blotting. Significant GLUT2 immunoreactivity was colocalized with colligin, an ER
marker, in confocal microscopy. Furthermore, the 55-kDa protein in HDM was labeled with a covalently reactive, impermeable glucose
transporter substrate, 1,3-bis-(3-deoxy-D-glucopyranose-3-yloxy)-2-propyl 4-benzoyl-benzoate (B3GL) when hepatocyte homogenates, but
not intact cells, were labeled. In addition glucose efflux from HDM vesicles was sensitive to B3GL treatment in a dose-dependent manner.
Based on these findings, we suggest that T3 may be a novel facilitative glucose transporter that is highly homologous to GLUT2 in the C-
terminal sequence, thus cross-reacting with the GLUT2 antibody. The finding will be useful in molecular identification and cloning of T3.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
A family of intrinsic membrane proteins (known as
facilitative glucose transporters or GLUTs) catalyzes the
glucose transport across the plasma membrane diffusion
barrier in animal cells [1]. GLUT2, an isoform of this
family, is selectively expressed in hepatocytes, pancreatic
beta cells, and absorptive renal and intestinal epithelial cells
[2]. The rate of glucose uptake in these cells, including
hepatocytes, greatly exceeds the rate of glucose metabolism,
thus GLUT2 at the cell surface does not appear to regulate
the overall glucose metabolism in these cells. On the other
hand, mutations in GLUT2 gene encoding nonfunctional
products have been identified in association with Fanconi-
Bickel syndrome [3], suggesting that GLUT2 may indeed
play a role in hepatic glucose metabolism (also see below).
The liver plays a key role in the glucose homeostasis; it
works as blood glucose ‘‘buffer’’, taking up or releasing
glucose depending on the level of blood glucose [4–6].
When glucose concentration in blood reaches 6 mM, the
liver takes up glucose and converts it to glucose-6-phosphate
(G6P). The liver can store a large amount of glucose as
glycogen but uses little glucose. During muscular activity or
after an overnight fasting, the blood glucose level drops to 4
mM, the liver now produces glucose by glycogenolysis or
gluconeogenesis and releases it into the blood. G6P occupies
a central crossroad position in these processes. It is produced
from glucose as the first step of glycolysis and glycogenesis,
the reaction catalyzed by glucokinase. Conversely, G6P is
converted to glucose as the terminal step of gluconeogenesis
and glycogenolysis. Glucose-6-phosphatase (G6Pase) cata-
lyzes this conversion. This conversion is an essential step in
glucose homeostasis, as only glucose, but not G6P, can leave
the liver into the blood stream, the process mediated by
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GLUT2. It is noteworthy in this regard that G6Pase is
selectively abundant in tissues where GLUT2 is expressed
[6]. The importance of hepatic glucose production in glucose
homeostasis has been well documented [7–9].
G6Pase is an integral membrane protein with its catalytic
activity residing in the lumen of endoplasmic reticulum
(ER) [10,11]. Its physiological function requires at least
five separate gene products [12], including transporters for
G6P (T1), pyrophosphate (T2) and glucose (T3). Of these,
T1 has been cloned [13]. This gene was found to be mutated
in glycogen storage disease type 1b patients whose G6P
transport function in ER was defective [9]. T3 mediates
glucose exit from the lumen of the ER back to the cytosol
[10]. Molecular identity of T3 is not known. GLUT2 is the
isoform presently identifiable in rat hepatocytes [2,3]. A
recent GLUT2 gene knock-out study [14] has shown that
the absence of GLUT2 expression does not affect hepatic
glucose production, suggesting that T3 is not GLUT2. This
led the authors to propose a nonconventional, vesicle-
mediated, glucose transport mechanism for glucose release
from hepatocyte ER to the blood. The proposal, however,
does not rule out the possibility that T3 may be a novel
GLUT isoform operating in the ER.
In subcellular fractionation followed by Western blot, we
have previously found that a GLUT2 antibody raised against
the peptide corresponding to the GLUT2 C-terminal 14-
amino-acid sequence recognizes a 55-kDa protein not only
in a plasma membrane-containing fraction but also in a
microsomal fraction of rat hepatocytes [15]. In the present
study, using an improved fractionation protocol, and assess-
ing subcellular distribution of several organelle-specific
markers, we now show that this GLUT2 immunoreactivity
detected in the microsomal fraction is not due to the plasma
membrane GLUT2 contamination but represents a protein in
the ER per se. This conclusion is also supported by immuno-
fluorescence confocal microscopy.More importantly, we also
show that a 55-kDa protein in the ER-enriched microsomal
fraction is labeled with a covalently active, membrane-
impermeable, glucose analog, B3GL, in cell homogenates,
but not in intact cells. Furthermore, we show that the HDM
vesicles transport glucose that is sensitive to B3GL treatment
in a dose-dependent manner. Together, these findings
strongly suggest that T3 may be a novel facilitative GLUT
isoform immunologically related to GLUT2. The covalent
labeling of a 55-kDa microsomal protein with B3GL together
with its apparent cross-reactivity to the GLUT2 antibody
would facilitate identification and cloning of T3.
2. Materials and methods
2.1. Materials
GLUT2 antibody was from Biogenesis (Brentwood, NH)
(Cat. No. RAGLUT2; Batch No. 160708B). Integrin-h1 and
calnexin antibody (N-terminus) were from Transduction
Laboratories (Lexington, KY). Na/K ATPase antibody was
from Upstate Technology (Lake Placid, NY). G6Pase anti-
body, a polyclonal antibody raised against the catalytic
portion of G6Pase [7], was a generous gift from Dr. Rebecca
Taub, University of Pennsylvania, Philadelphia, PA. Cal-
nexin antibody (C-terminus) was from StressGene Biotech-
nologies (Victoria, BC, Canada). Colligin antibody was
from StressGene Biotechnologies. Rabbit IgG and agarose
bound protein beads were from Vector Laboratories (Bur-
lingame, CA). Horseradish peroxidase (HRP)–protein A
was purchased from Zymed (San Francisco, CA). Trisacryl
bead (GF-2000) was obtained from Pierce (Rockford, IL).
ECL reagent was purchased from Amersham Pharmacia
Biotech (Buckinghamshire, England). Octylglucoside and
Triton X-100 were from Sigma (St. Louis, MI). 1,3-Bis-(3-
deoxy-D-glucopyranose-3-yloxy)-2-propyl 4-benzoyl-ben-
zoate (B3GL) was synthesized in our laboratory [16].
[3H]-D-glucose was purchased from ICN Pharmaceuticals
(Irvine, CA). Cellulose acetate/nitrate filters (0.22 Am pore)
were from Millipore. All other reagents were from sources
stated below and were of reagent grade.
2.2. Isolation of hepatocytes
Rats (Sprague–Dawley, male, 150–200 g body weight)
were anesthetized by sodium pentobarbital (40 mg/kg)
intramuscular injection, and the liver was perfused first with
400 ml Ca2 + -free Hank’s buffer (pH 7.4) containing EGTA
(5 mM) and D-glucose (5.5 mM) for 20 min, then with 100
ml of Hank’s buffer containing CaCI2 (2 mM) and collage-
nase (100 mg/150 ml). The liver was removed, incubated
with collagenase in 50 ml of buffer at 37 jC for 10 min, and
cells were filtered through a 60-Am nylon mesh. The cell
suspension was kept for 20 min at 4 jC to remove
erythrocytes, washed three times with cold Hank’s working
solution by centrifugation at 200 g (SS-34 rotor, 1000
rpm), and cells were resuspended in Krebs–Ringer phos-
phate buffer containing 2 mM pyruvate and 1% BSA, with
pH readjusted at 7.4. After 10 min incubation at 37 jC, cells
were separated by centrifugation and resuspended into the
same suspension buffer at a concentration of 1–2 106
cells/ml. Hepatocytes were counted by a Coulter electronic
particle counter. One rat liver typically gave 10–12 106
isolated hepatocytes or 3–4 ml of packed cells.
2.3. Subcellular fractionation
The procedures were modified from those described
previously [15,17], as follows. The hepatocytes were
packed by centrifugation at 2000 rpm (SS-34 rotor) for 3
min to make 50% cell suspension in homogenizing solution
containing 0.25 M sucrose and 10 mM HEPES, pH 7.4. The
cell suspension was aliquoted into 1 ml in Eppendorf tubes
and the cells were disrupted by passing 15 times through a
22-gauge needle with 1 ml tuberculin syringe and collected
each homogenate into a 40-ml centrifuge tube. Whole
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homogenate was centrifuged at 200 g (SS-34 rotor, 1000
rpm) for 3 min, the supernate was saved and the unbroken
cells in pellets were disrupted by the same method. This
procedure was repeated four times and the pooled supernate
was centrifuged at 1450 g (SS-34 rotor, 3500 rpm) for 10
min. The resultant pellet was used as a fraction containing
plasma membrane, nucleus, and mitochondria (PM/NM).
The supernate was further subjected to centrifugation at
25,000 g (SS-34 rotor, 14,500 rpm) for 10 min, and the
resulting pellet was used as a fraction enriched with lyso-
somes (LYSO). The 25,000 g supernate was centrifuged
at 48,000 g (50.2 rotor, 23,000 rpm) for 30 min and the
pellet was used as high-density microsomal fraction (HDM).
The 48,000 g supernate was then centrifuged at
200,000 g for 180 min to obtain a pellet of low-density
microsomal fraction (LDM).
2.4. Photoaffinity labeling with biotin-B3GL
Biotin-B3GL was prepared from B3GL by introducing
biotin via condensation of N-Fmoc-biocytin N-hydroxysuc-
cinimidyl ester with 2-amino-1,3-di-(1,2,4,5-diisopropyli-
dine-3-oxyl)-propane. After deprotecting, reaction with
succinimidyl ester of 4-benzoylbenzoic acid followed by
removal of isopropylidine protecting groups gave the bio-
tinylated analog (TLC by UV absorption, charring, reducing
sugar and presence of biotin; Rf = 0.43).
For labeling intact cells, hepatocytes (20–25% cytocrit)
were incubated for 30 min at 37 jC in Krebs Ringer
Phosphate (KRP) buffer (128 mM NaCl, 5.2 mM KCl, 1.2
mM CaCl2, 1.2 mM MgSO4, 1.29 mM KH2PO4, and 10
mM Na2HPO4, pH 7.4) containing 0.1% BSA and 2 mM
glucose or 1 mM pyruvate. For labeling broken cells, cells
were first homogenized as above in homogenizing solution
containing 0.25 M sucrose and 10 mM HEPES, pH 7.4. The
cell suspension or cell homogenates were then chilled in
cold BSA-free buffer (4 jC) mixed with 3.5 mM biotin-
labeled B3GL and 33 mM B3GL in a polypropylene dish.
The mixture was immediately irradiated on ice three times
for 20 s each with a 5-s intermission in between to swirl the
cell suspension gently. A 450-W mercury arc lamp (Conrad-
Hanovia, Newark, NJ) was used for irradiation at a distance
of 6.5 cm from a silica sleeve. A filter (C57-54, Corning
glass) was used to cut off radiation wavelength less than 280
nm. Following irradiation, the cells were immediately
washed twice with a 20-fold volume of prechilled, B3GL-
free incubation buffer to remove unbound biotin-B3GL. The
procedures are modified from those described previously
[16,18]. For glucose flux experiments, HDM vesicles were
treated as above without (control vesicles) or with a varying
concentration of B3GL with no biotin-B3GL.
2.5. Immunofluorescence confocal microscopy
The 5- to 10-mm-thick frozen sections of rat liver were
treated with 2% paraformaldehyde in PBS buffer (pH 7.4)
for 10 min, and subjected to a 10-min permeabilization with
0.1% Triton X-100, as described previously [8]. The slides
were washed in PBS buffer and incubated sequentially with
primary antibodies (rabbit polyclonal anti-Glut2 antibody
and mouse monoclonal anti-colligin antibody or Glut2 and
mouse monoclonal anti-integrin-h1 antibody), followed by
Texas-red-conjugated goat anti-rabbit and FITC-conjugated
donkey anti-mouse antibodies for GLUT2/colligin). After
the sections were washed with PBS buffer containing Triton
X-100 and covered with Prolong Antifade Reagent, they
Fig. 1. GLUT2, Na/K ATPase, integrin-h1, calnexin, and G6Pase Western blots of rat hepatocyte subcellular membrane fractions. Antibodies were used after
dilution in 1% milk/TTBS as specified in parentheses, and are anti-mouse integrin-h1 (2500 dilution); anti-rat Na/K ATPase a1 (rabbit polyclonal IgG)
(10,000 dilution); anti-mouse calnexin (C-terminus) (1000 dilution); anti-rabbit GLUT2 polyclonal antibody (750 dilution); and anti-rabbit G6Pase
(750 dilution) times in 1% milk/TTBS. Each lane contained 20 mg of membrane protein. The results were reproduced in three independent experiments.
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were visualized using a scanning laser confocal immuno-
fluorescence microscope.
2.6. Gel electrophoresis and Western blotting
Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) was performed as described [19] with a
slight modification as follows. Proteins were solubilized
with sample buffer containing 0.5% mercaptoethanol for 30
min at room temperature and applied 10–20 Ag of protein
onto 10% acrylamide gel. Gels were run with 150 constant
volts, and transferred to NC membrane for 1.5–2 h with 105
constant volts. The NC membranes were then blocked with
5% milk in TBS (50 mM Tris-base, 150 mM NaCl) for 30
min at room temperature with shaking, and incubated over-
night with primary antibody in 1% milk/TTBS (TBS + 0.1%
Tween 20). The membranes were washed three times with
TTBS for 10 min each, and incubated with secondary
antibody (HRP–protein A) in 1% milk/TTBS for 30 min
at room temperature with shaking. The membrane was then
reacted with ECL reagent for 1 min and exposed to X-ray
film at dark room. The X-ray films were developed at an
Autodeveloper and images were quantitated by densitom-
eter. For biotin-B3GL labeled membranes, the transferred
NC membranes were incubated overnight in 5% milk/TBS,
and incubated directly with streptoavidin–HRP at concen-
tration of 0.2 Ag/ml of 1% milk/TTBS for 30 min at room
temperature with shaking. The membranes were washed
three times with TBS for 10 min each, reacted with ECL
reagent for 1 min, and processed similarly as above.
Fig. 2. Subcellular distribution of the 55-kDa GLUT2, G6Pase, integrin and Na/K ATPase. The percentage distribution of the immunoreactivities (upper panel)
was calculated from the relative blotting intensities per unit protein mass and protein contents for each fraction. The relative blot intensities (lower panel) were
expressed in an arbitrary unit normalized against that of PM/NM. Calnexin data were not included in this analysis as it was confined to HDM fraction.
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2.7. Measurement of D-glucose flux across HDM vesicles
HDM vesicles before and after covalent labeling with
B3GL were used. Glucose flux across vesicles were meas-
ured according to Banhegyi et al. [20] using Millipore filters
with a minor modification. Briefly, HDM vesicles (1 mg/ml)
in 10 mM HEPES buffer, pH 7.4, containing 0.25 M sucrose
were preloaded with 20 mM glucose in the presence of a
tracer amount of [3H]glucose (10 ACi/ml) for 1 h at room
temperature, recovered as pellets by centrifugation at
48,000 g for 30 min, and were transferred into a 10-fold
volume of glucose-free 10 mM HEPES buffer, pH 7.4,
containing 0.25 M sucrose (efflux assay buffer) at time
equal zero. Sample aliquots were taken at specified time
intervals, filtered through Millipore filters, and quickly
washed four times, each time with 2-fold volume of ice-
cold, efflux assay buffer containing 2 mM mercuric chlor-
ide. The radioactivity on the filters was measured in LKB
liquid scintillation counter.
3. Results
3.1. GLUT2 immunoreactivity in a plasma membrane-free
microsomal fraction of rat hepatocytes
GLUT2 is responsible for the cellular uptake and release
of glucose in hepatocytes [2]. Using polyclonal GLUT2
antibody raised against the GLUT2 C-terminal 14-amino-
acid-sequence peptide, we have previously detected a broad
55-kDa protein band as the major immunoreactive protein in
total hepatocyte membranes, with a 38-kDa protein as a
minor immunoreactive protein [19]. Digestion with Endo-F/
peptide-N-glucosidase converted the 55-kDa protein to a 38-
kDa protein (unpublished observation), indicating that the
38-kDa protein is, at least in part, a nonglycosylated,
immature form of GLUT2, whereas the 55-kDa protein
being the fully glycosylated, matured GLUT2. Upon sub-
cellular fractionation, both the 55-kDa and 38-kDa GLUT2
immunoreactive protein species were detected in PM/NM,
LYSO and HDM fractions but not in LDM fraction (Fig. 1).
Alternatively, a 38-kDa band may represent a proteolytic
fragment of the GLUT2 immunoreactive 55-kDa protein.
Relative contents of selected membrane proteins in each
of these subcellular membrane fractions were also assessed
(Fig. 1). The two well-known plasma membrane markers,
integrin-h1 and Na/K ATPase, were present in PM/NM and
LYSO, but not in HDM and LDM. Calnexin, an ER marker,
on the other hand, was present abundantly in HDM, only
slightly if any in LYSO, and totally absent in PM/NM and
LDM. Together, these findings clearly indicate that the
plasma membrane is present only in PM/NM and LYSO
fractions, but not in HDM or LDM. The findings also
indicate that the ER is quantitatively recovered in HDM
fraction, and is effectively excluded from PM/NM, LYSO,
and LDM.
The detection of GLUT2 immunoreactivity in PM/NM
and LYSO is expected from the presence of the two plasma
membrane markers integrin-h1 and Na/K ATPase in these
fractions. Our detection of abundant GLUT2 immunoreac-
tivity in HDM, the fraction virtually free of the two plasma
membrane markers (Fig. 1), however, strongly suggests that
the GLUT2 immunoreactivity in HDM is not due to the
plasma membrane GLUT2 contamination. Interestingly, a
significant amount of G6Pase was detected in PM/NM
fraction in immunoblots (Fig. 1), most likely due to apparent
association of this enzyme with the nuclear envelop [21].
Semi-quantitative analyses of the blotting intensities and
the percentage distribution of the 55-kDa GLUT2 and other
relevant membrane proteins among different fractions are
summarized in Fig. 2. Significantly, as much as 18.2F 1.8%
(a meanF S.D., calculated from results of four experiments)
of the cellular 55-kDa GLUT2 immunoreactivity is in
HDM, the fraction that is free of plasma membrane con-
tamination. Moreover, the relative intensity of the 55-kDa
GLUT2 immunoreactivity, expressed per unit protein mass
(lower panel) is significantly greater in HDM than in PM/
NM and LYSO, clearly indicating that the immunoreactivity
in HDM is not due to possible plasma membrane contam-
ination. Similarly, only 20% or less of the cellular G6Pase is
detected in HDM, suggesting that a large portion of cellular
G6Pase reside in membranes other than the ER, including
Fig. 3. Covalent labeling of hepatocyte membrane proteins with B3GL. The
photolabeling procedures were essentially those used for labeling GLUT4
in rat adipocytes [22]. Hepatocytes before (intact cells) and after
homogenization (broken cells) were used for the plasma membrane-
selective, and total cellular GLUT2 covalent labeling, respectively. Intact
cells or homogenates were suspended in an ice-cold solution of biotinylated
B3GL and B3GL (in 1–10 M ratio) in TBS, and irradiated using a 450-W
mercury lamp at 6.5 cm from the silica sleeve through a layer of water as
heat filter. The irradiated cells were washed extensively with ice-cold TBS
before homogenization and subcellular fractionation. When broken cells
were labeled (broken cells), cells were homogenized without or with
fractionation before photolabeling. Proteins in each subcellular fraction
were resolved in SDS-PAGE and Biotin-B3GL label was quantitated based
on biotin– streptavidin–HRP interactions.
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the nuclear membranes [21]. The relatively low blotting
intensities (per unit protein mass) of integrin-h1 and Na/K
ATPase, the two plasma membrane markers tested, in PM/
NM compared to LYSO and HDM, is in part due to large
nuclei and mitochondria (NM) protein (65–70%) in this
fraction.
3.2. A 55-kDa microsomal protein is labeled with B3GL in
cell homogenates but not in intact cells
B3GL, a membrane-impermeable, photolytically active,
glucose analog, has been used to label the plasma membrane
GLUT4 selectively without labeling microsomal GLUT4
pool in intact rat adipocytes [16,18]. B3GL is surface-
selective and not GLUT protein-selective in certain cell
types; since it labels a 70-kDa membrane protein of
unknown identity, in addition to GLUT protein in adipo-
cytes [16,18]. On the other hand, B3GL labeling in human
erythrocytes is specific to GLUT1; it labels a single 45-kDa
membrane protein that is photolytically labeled by cytocha-
lasin B (unpublished observation).
Rat hepatocytes were labeled with biotin-B3GL and
subjected to subcellular fractionation as described in Mate-
rials and Methods. When intact cells were used for the
photolysis, it resulted in labeling of 55-kDa and 38-kDa
membrane proteins in PM/NM and LYSO fractions, but not
in HDM fraction (Fig. 3). However, when the same labeling
procedure was repeated after cells were first homogenized
(broken cells), both 55-kDa and 38-kDa proteins were
labeled not only in PM/NM and LYSO fractions, but also
in HDM fraction as well (Fig. 3). A straightforward inter-
pretation of these findings would be that the B3GL-labeled
55-kDa and 38-kDa proteins detected in HDM were not
accessible to the B3GL labeling in intact cells, but became
accessible in broken cells. This is a strong support that the
labeled 55-kDa protein in HDM is not a contaminating
plasma membrane protein, namely, the plasma membrane
GLUT2. The electrophoretic mobility of the 55-kDa B3GL-
labeled protein was indistinguishable from that of the
GLUT2 immunoreactivity in each of these fractions (not
illustrated). Furthermore, the relative intensities of the
B3GL labeling among different fractions from broken cells
Fig. 4. Confocal images showing rat hepatocytes double immunofluorescence labeled with GLUT2 and integrin-h1 (A–C) or colligin (D–F). Cells fixed,
permeabilized, and incubated with polyclonal antibody against GLUT2 (A and D) and monoclonal antibody against integrin-h1 (B) or mouse monoclonal anti-
colligin antibody (E). The secondary antibodies used were Texas-red-conjugated goat anti-rabbit (A), FITC-conjugated donkey anti-mouse (B), FITC-
conjugated goat anti-rabbit (D), and Cy5-conjugated donkey anti-mouse (E) antibodies. Note that GLUT2 antibody staining is evident not only at the cell
surface but also with particulate structure throughout the cytoplasmic space (A and D). This is in contrast to the selective staining of the cell surface and
intracellular structure by integrin-h1 (B) and colligin (E), respectively. The extensive colocalization of GLUT2 with integrin-h1 at the cell surface, but not in
the cytoplasmic space, is evident and visible as yellow-orange fluorescence overlaying A and B (C). Also evident is the intracellular, but not the plasma
membrane, colocalization of GLUT2 with colligin, visible as orange fluorescence by overlaying D and E (F). Each picture was delivered at 600
magnification.
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are remarkably similar to the relative GLUT2 immunoblot
intensities (Fig. 3), suggesting that the B3GL-labeled pro-
tein in HDM is most likely the protein recognized by the
GLUT2 antibody in immunoblots.
3.3. Colocalization of GLUT2 immunoreactivity with an ER
marker, colligin, in intact hepatocytes
The presence of the GLUT2 immunoreactive entity in the
ER in hepatocytes is further supported by immunofluores-
cence confocal microscopy (Fig. 4). Integrin-h1 immunos-
taining was highly intense at the cell surface, but
conspicuously absent throughout the intracellular space
(Fig. 4, panel B). Colligin immunostaining, on the other
hand, clearly revealed numerous punctuate labeling of intra-
cellular structures with little cell surface labeling (Fig. 4,
panel E). These findings confirm that integrin-h1 and
colligin are selective markers for the plasma membrane
and the ER, respectively. Colligin is known to reside
selectively in the ER [22]. The calnexin antibody used for
immunoblots did not give a good-quality immunostaining
for the microscopy.
Significantly, the GLUT2 immunostaining was not only
highly concentrated at the cell surface, but also to a
significant extent distributed throughout the intracellular
space (Fig. 4, panels A and D). This is in contrast to the
total lack of integrin-h1 staining throughout intracellular
space discussed above (Fig. 4, panel B), and indicates the
presence of GLUT2 immunoreactivity in the intracellular
compartments. The GLUT2 immunoreactivity in the ER is
further confirmed by double staining for GLUT2 and
colligin. Most of the intracellular GLUT2 staining was
overlapped with colligin staining showing orange, while
that of cell surface was not (Fig. 4, panel F). This is in
contrast to the overlay of GLUT2 and integrin-h1 double
labeling image (Fig. 4, panel C) where GLUT2 staining was
overlapped with integrin-h1 staining at the cell surface, but
not in the intracellular compartments.
3.4. Demonstration of B3GL-sensitive glucose efflux in
HDM vesicles
To study transport property of T3 in HDM fraction and
its relationship to the 55-kDa protein that is labeled with
B3GL in cell homogenates but not in intact cells, we
measured glucose efflux from glucose-loaded HDM vesicles
before and after covalent labeling with B3GL (Fig. 5). HDM
vesicles showed a glucose efflux that was effectively
arrested by cold temperature and 2 mM mercury chloride.
Although our efflux time course measurements were not
rigorous enough to detect the fast and slow flux components
reported previously (20), the following points are never-
theless clear and noteworthy: The flux was relatively rapid,
showing a 50% net loss of glucose content in vesicles
occurred at around 1 min. The efflux was also sensitive to
N-ethylmaleimide, being inhibited by more than 80% in the
presence of 5 mM N-ethylmaleimide. Most notably, the
covalent labeling of HDM vesicles with 10 and 30 mM
B3GL reduced the rate of glucose efflux significantly and in
a dose-dependent manner, showing a 50% net loss at
approximately 2 and 4 min, respectively. The findings are
consistent with the interpretation that the glucose transport
across the hepatocyte HDM vesicles is mediated by a
protein, namely T3, the 55-kDa protein that was labeled
by B3GL only in isolated vesicles but not in intact cells
(Fig. 3).
4. Discussion
Here we have shown that there is a 55-kDa protein in an
ER-enriched microsomal fraction of hepatocytes that is
recognized by a GLUT2 antibody and also reacts with a
covalently active, glucose analog, B3GL. We also detected a
38-kDa protein as a minor species recognized by the
GLUT2 antibody as well as by B3GL labeling. Although
the identity of this band is unknown, the possibilities
include proteolytic fragment of GLUT2 and/or unglycosy-
lated GLUT2. The 55-kDa protein in HDM is not a con-
taminating plasma membrane protein, but actually resides in
the ER. The following findings support this conclusion:
First, the ER-enriched microsomal fraction is totally devoid
of two plasma membrane markers, namely, integrin-h1 and
Fig. 5. Glucose efflux from glucose-preloaded hepatocyte HDM vesicles.
Vesicles before and after covalent labeling with B3GL were loaded with 20
mM glucose in the presence of a tracer amount of [3H]glucose. Glucose-
loaded vesicles were resuspended in a glucose-free buffer at time equal zero
and a 4-min time course of changes in vesicular glucose content was
followed as detailed in Materials and Methods. Glucose contents in vesicles
were measured based on radioactive tracer expressed in cpm on the Y-axis.
Data are means of two to three independent measurements. Symbols are
with vesicles before B3GL treatment and no additive (circles), with vesicles
before B3GL treatment and in the presence of 5 mM N-ethylmaleimide
(triangles), with vesicles after treatment with 10 mM B3GL (squares) or
with 30 mM B3GL (diamonds) with no additive.
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Na/K ATPase, but contains practically all of the cellular
calnexin (Figs. 1 and 2). Second, B3GL labeling of the 55-
kDa protein in the ER-enriched fraction occurs only when
broken cells, but not intact cells, were used for the labeling
(Fig. 3). Finally, immunofluorescence confocal microscopic
findings (Fig. 4), the assay method that does not involve
subcellular fractionation, thus free from homogenization
artifacts, also support the presence of a significant portion
of GLUT2 immunoreactivity in microsomes, most likely in
the ER, in addition to the plasma membrane. Most of the
cellular GLUT2 immunoreactivity is in the plasma mem-
brane. The non-plasma membrane microsomal GLUT2
immunoreactivity amounts to 17–19% of the total cellular
GLUT2 immunoreactivity (Fig. 2). The putative GLUT2
immunoreactivity in the ER could be significantly less than
this estimate as immunofluorescence confocal microscopy
data (Fig. 4) would suggest.
Here we have also demonstrated the presence of a protein-
mediated rapid glucose flux across HDM vesicles as indi-
cated by its sensitivity to low temperature and the inhibition
by mercury chloride and N-ethylmaleimide (Fig. 5) and that
this glucose flux is inactivated after covalent reaction with
B3GL in a dose-dependent manner (Fig. 5). These findings
strongly suggest that the 55-kDa protein in HDM labeled by
B3GL and recognized by a GLUT2 antibody is indeed T3.
As to the relationship between GLUT2 and T3, it is possible
that GLUT2 is present not only at the plasma membrane but
also may be present in the ER and function as T3. This
possibility, however, is not supported by the recent demon-
stration [14] that the hepatic glucose production, including
the putative T3 function [23], is normal in the absence of
GLUT2 expression. It is now more likely that T3 may be a
novel isoform of the facilitative GLUT family. Our demon-
stration that a 55-kDa protein of microsomal origin is labeled
by B3GL, a covalently active GLUT substrate (Fig. 3), is
clearly in favor of this possibility. The role of such a protein,
on the other hand, is less obvious in the alternative glucose
transport pathway involving vesicle translocation that these
authors have suggested [14,23]. Recently, a number of new
GLUT isoforms have been cloned [24–26], thus it is not
surprising to expect a new isoform in this family. The novel
GLUT isoform proposed here could be closely related to
GLUT2 at least in partial amino acid sequence in its C-
terminal cytoplasmic domain, as suggested by its apparent
recognition by the GLUT2 antibody raised against the
peptide corresponding to the GLUT2 C-terminal amino acid
sequences.
Transport property of T3 has been partially characterized
by studying glucose flux using hepatocyte ER-containing
microsomal preparations and shown to be significantly
different from that of GLUT isoforms [10,27–29]. In con-
trast to all other GLUT isoforms now known, T3 was shown
to be not inhibited by cytochalasin B, and accepts L-glucose
as a substrate. T3 was also known to show the Vmax and Km
to glucose much larger than GLUT2. Because of the large
surface area-to-volume ratio inherent to these microsomal
preparations, the accurate assay for rapid flux such as that of
glucose is technically difficult, and it is not known how
much of these differences are real and not an experimental
artifact. The rapid L-glucose flux observed also could be due
to leaky microsomes. A novel approach is needed to
confirm free of experimental artifact the apparent difference
between T3 and GLUT properties. Although the data shown
in the present study do not offer unequivocal evidence that
T3 function coincides with the 55-kDa protein in HDM
constituting a GLUT2 variant, they do provide critical
information useful in future studies of the molecular iden-
tification and cloning of T3.
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